| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Non-Small-Cell Lung | 25 | 2022 | 1130 | 5.030 |
Why?
|
| Lung Neoplasms | 33 | 2022 | 2363 | 4.600 |
Why?
|
| Chemoradiotherapy | 19 | 2022 | 327 | 3.550 |
Why?
|
| Radiosurgery | 15 | 2025 | 319 | 3.440 |
Why?
|
| Carcinoma, Squamous Cell | 14 | 2021 | 1073 | 2.860 |
Why?
|
| Hodgkin Disease | 6 | 2016 | 144 | 2.030 |
Why?
|
| Neoplasm Staging | 36 | 2022 | 2009 | 2.020 |
Why?
|
| Oropharyngeal Neoplasms | 7 | 2022 | 149 | 1.980 |
Why?
|
| Neoadjuvant Therapy | 12 | 2017 | 446 | 1.940 |
Why?
|
| Adenocarcinoma | 9 | 2020 | 1171 | 1.880 |
Why?
|
| Radiotherapy, Intensity-Modulated | 8 | 2019 | 190 | 1.580 |
Why?
|
| Databases, Factual | 15 | 2022 | 1004 | 1.530 |
Why?
|
| Brain Neoplasms | 10 | 2025 | 810 | 1.380 |
Why?
|
| Carcinoma, Large Cell | 4 | 2021 | 37 | 1.230 |
Why?
|
| Middle Aged | 65 | 2025 | 27535 | 1.220 |
Why?
|
| Chemoradiotherapy, Adjuvant | 6 | 2020 | 39 | 1.210 |
Why?
|
| Aged | 55 | 2025 | 20395 | 1.160 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 8 | 2019 | 214 | 1.140 |
Why?
|
| Male | 75 | 2025 | 44355 | 1.140 |
Why?
|
| Glioblastoma | 5 | 2025 | 280 | 1.130 |
Why?
|
| Papillomavirus Infections | 5 | 2022 | 301 | 1.080 |
Why?
|
| Female | 74 | 2025 | 48542 | 1.050 |
Why?
|
| Chemotherapy, Adjuvant | 5 | 2019 | 512 | 1.050 |
Why?
|
| Aged, 80 and over | 29 | 2025 | 7039 | 0.990 |
Why?
|
| Radiotherapy Dosage | 13 | 2019 | 477 | 0.960 |
Why?
|
| SEER Program | 17 | 2025 | 235 | 0.940 |
Why?
|
| Small Cell Lung Carcinoma | 3 | 2022 | 129 | 0.930 |
Why?
|
| United States | 32 | 2025 | 7581 | 0.920 |
Why?
|
| Survival Rate | 17 | 2025 | 1945 | 0.890 |
Why?
|
| Humans | 97 | 2025 | 93132 | 0.890 |
Why?
|
| Survival Analysis | 14 | 2019 | 1518 | 0.880 |
Why?
|
| Adult | 49 | 2025 | 27849 | 0.860 |
Why?
|
| Kaplan-Meier Estimate | 13 | 2020 | 874 | 0.850 |
Why?
|
| Registries | 6 | 2025 | 995 | 0.850 |
Why?
|
| Young Adult | 28 | 2025 | 6922 | 0.850 |
Why?
|
| Neoplasm, Residual | 3 | 2016 | 196 | 0.840 |
Why?
|
| Combined Modality Therapy | 14 | 2019 | 1719 | 0.840 |
Why?
|
| Proportional Hazards Models | 14 | 2020 | 888 | 0.840 |
Why?
|
| Early Detection of Cancer | 4 | 2021 | 504 | 0.830 |
Why?
|
| Palliative Care | 3 | 2018 | 268 | 0.820 |
Why?
|
| Follow-Up Studies | 18 | 2024 | 3814 | 0.770 |
Why?
|
| Transplantation Conditioning | 7 | 2025 | 383 | 0.740 |
Why?
|
| Esophageal Neoplasms | 3 | 2016 | 343 | 0.730 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2024 | 1447 | 0.730 |
Why?
|
| Neoplasms, Second Primary | 2 | 2015 | 244 | 0.660 |
Why?
|
| Healthcare Disparities | 5 | 2021 | 496 | 0.640 |
Why?
|
| Extremities | 2 | 2013 | 170 | 0.620 |
Why?
|
| Adolescent | 20 | 2025 | 9550 | 0.620 |
Why?
|
| Nasopharyngeal Neoplasms | 2 | 2017 | 46 | 0.620 |
Why?
|
| Lymph Nodes | 4 | 2020 | 550 | 0.610 |
Why?
|
| Radiotherapy, Conformal | 3 | 2017 | 87 | 0.610 |
Why?
|
| Sarcoma | 2 | 2013 | 220 | 0.600 |
Why?
|
| Retrospective Studies | 26 | 2024 | 10128 | 0.590 |
Why?
|
| Multivariate Analysis | 9 | 2017 | 984 | 0.580 |
Why?
|
| Prognosis | 14 | 2022 | 3890 | 0.570 |
Why?
|
| Cohort Studies | 13 | 2020 | 3044 | 0.550 |
Why?
|
| Treatment Outcome | 19 | 2022 | 9070 | 0.550 |
Why?
|
| Radiotherapy, Adjuvant | 9 | 2020 | 314 | 0.550 |
Why?
|
| Health Services Accessibility | 2 | 2021 | 480 | 0.540 |
Why?
|
| Stomach Neoplasms | 3 | 2017 | 305 | 0.530 |
Why?
|
| Carcinoma | 5 | 2022 | 439 | 0.530 |
Why?
|
| Tongue Neoplasms | 1 | 2017 | 51 | 0.520 |
Why?
|
| Hospitals, Low-Volume | 1 | 2017 | 23 | 0.520 |
Why?
|
| Mass Screening | 2 | 2021 | 706 | 0.520 |
Why?
|
| Cytoreduction Surgical Procedures | 3 | 2025 | 92 | 0.510 |
Why?
|
| Hospitals, High-Volume | 1 | 2017 | 42 | 0.510 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 5 | 2025 | 940 | 0.490 |
Why?
|
| Tomography, X-Ray Computed | 7 | 2021 | 2562 | 0.480 |
Why?
|
| Mouth Neoplasms | 2 | 2020 | 202 | 0.480 |
Why?
|
| Esophagectomy | 3 | 2016 | 92 | 0.450 |
Why?
|
| Whole-Body Irradiation | 5 | 2025 | 70 | 0.450 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2020 | 618 | 0.440 |
Why?
|
| Thoracic Neoplasms | 1 | 2015 | 64 | 0.440 |
Why?
|
| Induction Chemotherapy | 1 | 2016 | 146 | 0.440 |
Why?
|
| Insurance, Health | 5 | 2016 | 175 | 0.430 |
Why?
|
| Propensity Score | 8 | 2020 | 178 | 0.430 |
Why?
|
| Mortality | 2 | 2016 | 156 | 0.430 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2025 | 2543 | 0.430 |
Why?
|
| Insurance Coverage | 4 | 2017 | 141 | 0.420 |
Why?
|
| Tumor Burden | 6 | 2020 | 321 | 0.400 |
Why?
|
| Preoperative Care | 2 | 2017 | 404 | 0.400 |
Why?
|
| Central Nervous System | 1 | 2014 | 139 | 0.380 |
Why?
|
| Immunotherapy | 1 | 2019 | 762 | 0.380 |
Why?
|
| Radiation Injuries | 1 | 2014 | 156 | 0.380 |
Why?
|
| Pneumonectomy | 1 | 2015 | 217 | 0.370 |
Why?
|
| Organs at Risk | 5 | 2019 | 55 | 0.370 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2014 | 278 | 0.350 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2015 | 1000 | 0.340 |
Why?
|
| Disease-Free Survival | 5 | 2020 | 1171 | 0.340 |
Why?
|
| Ependymoma | 1 | 2011 | 28 | 0.340 |
Why?
|
| Breast Neoplasms | 6 | 2015 | 3155 | 0.310 |
Why?
|
| Logistic Models | 4 | 2020 | 1240 | 0.310 |
Why?
|
| Socioeconomic Factors | 3 | 2017 | 627 | 0.310 |
Why?
|
| Lymphatic Metastasis | 5 | 2020 | 505 | 0.300 |
Why?
|
| Brachytherapy | 3 | 2015 | 128 | 0.300 |
Why?
|
| Papillomaviridae | 4 | 2022 | 179 | 0.290 |
Why?
|
| Myeloablative Agonists | 3 | 2025 | 38 | 0.290 |
Why?
|
| Busulfan | 3 | 2025 | 41 | 0.290 |
Why?
|
| Radiation Oncology | 4 | 2018 | 125 | 0.290 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2009 | 124 | 0.280 |
Why?
|
| Prostatic Neoplasms | 5 | 2020 | 1769 | 0.280 |
Why?
|
| Gallbladder Neoplasms | 1 | 2008 | 23 | 0.280 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2008 | 23 | 0.270 |
Why?
|
| Lymph Node Excision | 3 | 2020 | 233 | 0.270 |
Why?
|
| Head and Neck Neoplasms | 3 | 2022 | 1071 | 0.260 |
Why?
|
| Clinical Clerkship | 3 | 2014 | 119 | 0.260 |
Why?
|
| Vidarabine | 2 | 2025 | 93 | 0.260 |
Why?
|
| Dacarbazine | 2 | 2017 | 100 | 0.240 |
Why?
|
| Salivary Gland Neoplasms | 2 | 2021 | 81 | 0.240 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 2 | 2018 | 67 | 0.240 |
Why?
|
| Vipoma | 1 | 2025 | 4 | 0.230 |
Why?
|
| Comorbidity | 3 | 2020 | 1003 | 0.230 |
Why?
|
| Shock | 1 | 2025 | 46 | 0.220 |
Why?
|
| Transplantation, Homologous | 2 | 2025 | 1014 | 0.220 |
Why?
|
| Regression Analysis | 3 | 2017 | 573 | 0.220 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2005 | 96 | 0.220 |
Why?
|
| Diarrhea | 1 | 2025 | 176 | 0.210 |
Why?
|
| Child, Preschool | 4 | 2015 | 3781 | 0.210 |
Why?
|
| Anemia, Sickle Cell | 2 | 2018 | 145 | 0.210 |
Why?
|
| Patient Selection | 2 | 2020 | 688 | 0.210 |
Why?
|
| Cisplatin | 2 | 2016 | 567 | 0.210 |
Why?
|
| Osteosarcoma | 1 | 2005 | 156 | 0.210 |
Why?
|
| Child | 5 | 2015 | 7273 | 0.210 |
Why?
|
| Prevalence | 3 | 2020 | 1318 | 0.200 |
Why?
|
| Radiotherapy | 3 | 2016 | 319 | 0.200 |
Why?
|
| Meningioma | 1 | 2024 | 62 | 0.200 |
Why?
|
| Meningeal Neoplasms | 1 | 2024 | 69 | 0.190 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 2 | 2020 | 17 | 0.190 |
Why?
|
| Academic Medical Centers | 2 | 2016 | 396 | 0.190 |
Why?
|
| Postoperative Care | 2 | 2017 | 232 | 0.190 |
Why?
|
| Analysis of Variance | 3 | 2017 | 883 | 0.190 |
Why?
|
| Bone Neoplasms | 2 | 2021 | 308 | 0.190 |
Why?
|
| Neoplasm Grading | 5 | 2020 | 401 | 0.190 |
Why?
|
| Career Choice | 2 | 2014 | 153 | 0.180 |
Why?
|
| Intracranial Arteriovenous Malformations | 1 | 2022 | 121 | 0.180 |
Why?
|
| Neoplasm Invasiveness | 3 | 2017 | 570 | 0.170 |
Why?
|
| Mastectomy | 3 | 2015 | 262 | 0.170 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2021 | 40 | 0.170 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2021 | 43 | 0.160 |
Why?
|
| Odontogenic Tumors | 1 | 2020 | 11 | 0.160 |
Why?
|
| Neoplasms | 4 | 2017 | 3168 | 0.160 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2022 | 267 | 0.160 |
Why?
|
| Time-to-Treatment | 1 | 2021 | 140 | 0.150 |
Why?
|
| Pancreatic Neoplasms | 1 | 2025 | 714 | 0.150 |
Why?
|
| Liver Neoplasms | 1 | 2025 | 773 | 0.150 |
Why?
|
| Curriculum | 2 | 2014 | 590 | 0.150 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2017 | 134 | 0.150 |
Why?
|
| Risk Factors | 4 | 2020 | 5900 | 0.140 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 2018 | 18 | 0.140 |
Why?
|
| Transplantation, Haploidentical | 1 | 2018 | 28 | 0.140 |
Why?
|
| Glossectomy | 1 | 2017 | 4 | 0.130 |
Why?
|
| Risk Assessment | 3 | 2024 | 2434 | 0.130 |
Why?
|
| Reward | 1 | 2020 | 209 | 0.130 |
Why?
|
| Hyperthermia, Induced | 1 | 2018 | 75 | 0.130 |
Why?
|
| Oral Surgical Procedures | 1 | 2017 | 19 | 0.130 |
Why?
|
| Minority Groups | 1 | 2018 | 149 | 0.130 |
Why?
|
| Thymoma | 1 | 2017 | 31 | 0.120 |
Why?
|
| Endosonography | 1 | 2017 | 100 | 0.120 |
Why?
|
| Guideline Adherence | 2 | 2015 | 237 | 0.120 |
Why?
|
| Functional Laterality | 1 | 2017 | 204 | 0.120 |
Why?
|
| Organ Transplantation | 1 | 2020 | 295 | 0.120 |
Why?
|
| Peritoneal Neoplasms | 1 | 2018 | 183 | 0.120 |
Why?
|
| Thymus Neoplasms | 1 | 2017 | 46 | 0.120 |
Why?
|
| Practice Guidelines as Topic | 2 | 2021 | 1054 | 0.120 |
Why?
|
| Bronchi | 1 | 2017 | 224 | 0.120 |
Why?
|
| Prostate | 1 | 2020 | 416 | 0.120 |
Why?
|
| Margins of Excision | 1 | 2016 | 45 | 0.120 |
Why?
|
| Cancer Care Facilities | 1 | 2016 | 36 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2019 | 3450 | 0.120 |
Why?
|
| Time Factors | 2 | 2017 | 5380 | 0.120 |
Why?
|
| Private Sector | 1 | 2015 | 20 | 0.110 |
Why?
|
| Taxoids | 1 | 2016 | 126 | 0.110 |
Why?
|
| Head | 1 | 2016 | 131 | 0.110 |
Why?
|
| Carboplatin | 1 | 2016 | 321 | 0.110 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2016 | 103 | 0.110 |
Why?
|
| Immunosuppressive Agents | 1 | 2020 | 987 | 0.110 |
Why?
|
| Social Class | 1 | 2016 | 142 | 0.110 |
Why?
|
| Odds Ratio | 1 | 2017 | 709 | 0.110 |
Why?
|
| Relative Biological Effectiveness | 1 | 2015 | 14 | 0.110 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2015 | 50 | 0.110 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2015 | 165 | 0.110 |
Why?
|
| Mesothelioma | 1 | 2018 | 331 | 0.110 |
Why?
|
| Epidemiologic Methods | 1 | 2015 | 60 | 0.110 |
Why?
|
| Confidence Intervals | 2 | 2015 | 217 | 0.110 |
Why?
|
| Population Surveillance | 1 | 2016 | 212 | 0.110 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2015 | 193 | 0.110 |
Why?
|
| Disease Management | 1 | 2017 | 357 | 0.110 |
Why?
|
| Community Health Services | 1 | 2015 | 79 | 0.110 |
Why?
|
| Needs Assessment | 2 | 2014 | 167 | 0.110 |
Why?
|
| Fluorouracil | 1 | 2016 | 524 | 0.110 |
Why?
|
| Unrelated Donors | 1 | 2014 | 47 | 0.110 |
Why?
|
| Program Evaluation | 2 | 2014 | 312 | 0.100 |
Why?
|
| Graft Survival | 1 | 2018 | 939 | 0.100 |
Why?
|
| Students, Medical | 3 | 2014 | 433 | 0.100 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 2787 | 0.100 |
Why?
|
| Multiple Myeloma | 1 | 2017 | 336 | 0.100 |
Why?
|
| Necrosis | 1 | 2014 | 203 | 0.100 |
Why?
|
| Phantoms, Imaging | 1 | 2016 | 479 | 0.100 |
Why?
|
| Sex Factors | 2 | 2021 | 1102 | 0.100 |
Why?
|
| Bone Marrow | 2 | 2025 | 408 | 0.100 |
Why?
|
| Bevacizumab | 1 | 2014 | 254 | 0.090 |
Why?
|
| Endometrial Neoplasms | 1 | 2015 | 226 | 0.090 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2015 | 317 | 0.090 |
Why?
|
| Clinical Competence | 2 | 2014 | 810 | 0.090 |
Why?
|
| Length of Stay | 1 | 2015 | 820 | 0.090 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2011 | 165 | 0.080 |
Why?
|
| Patient Readmission | 1 | 2015 | 403 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 1703 | 0.080 |
Why?
|
| Hematologic Neoplasms | 1 | 2014 | 372 | 0.080 |
Why?
|
| Lymphatic Irradiation | 1 | 2010 | 7 | 0.080 |
Why?
|
| Thoracic Wall | 1 | 2010 | 26 | 0.080 |
Why?
|
| Remission Induction | 1 | 2011 | 737 | 0.070 |
Why?
|
| Postoperative Complications | 1 | 2020 | 2552 | 0.070 |
Why?
|
| Recurrence | 2 | 2025 | 1188 | 0.070 |
Why?
|
| Gastrectomy | 2 | 2017 | 71 | 0.060 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2008 | 160 | 0.060 |
Why?
|
| Quality of Life | 1 | 2015 | 1776 | 0.060 |
Why?
|
| Retinoblastoma | 1 | 2005 | 30 | 0.060 |
Why?
|
| Rhabdomyosarcoma | 1 | 2005 | 42 | 0.060 |
Why?
|
| Sarcoma, Ewing | 1 | 2005 | 42 | 0.060 |
Why?
|
| Biopsy | 1 | 2008 | 1172 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2008 | 1519 | 0.050 |
Why?
|
| Allografts | 2 | 2015 | 205 | 0.050 |
Why?
|
| Graft vs Host Disease | 1 | 2025 | 365 | 0.050 |
Why?
|
| Age Factors | 2 | 2020 | 1898 | 0.050 |
Why?
|
| Medicaid | 2 | 2015 | 245 | 0.040 |
Why?
|
| Cetuximab | 1 | 2022 | 118 | 0.040 |
Why?
|
| Mastectomy, Segmental | 2 | 2012 | 108 | 0.040 |
Why?
|
| Eligibility Determination | 1 | 2021 | 39 | 0.040 |
Why?
|
| Medical History Taking | 1 | 2021 | 80 | 0.040 |
Why?
|
| Cerebrovascular Circulation | 1 | 2022 | 229 | 0.040 |
Why?
|
| Hypopharyngeal Neoplasms | 1 | 2020 | 15 | 0.040 |
Why?
|
| Chicago | 2 | 2016 | 1452 | 0.040 |
Why?
|
| Cigarette Smoking | 1 | 2021 | 47 | 0.040 |
Why?
|
| Laryngeal Neoplasms | 1 | 2020 | 89 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2005 | 2427 | 0.040 |
Why?
|
| Lung | 2 | 2016 | 1359 | 0.040 |
Why?
|
| Infant | 1 | 2005 | 3156 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 290 | 0.030 |
Why?
|
| Cranial Irradiation | 1 | 2018 | 42 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2021 | 806 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2017 | 4546 | 0.030 |
Why?
|
| Retreatment | 1 | 2017 | 104 | 0.030 |
Why?
|
| Melphalan | 1 | 2017 | 98 | 0.030 |
Why?
|
| Machine Learning | 1 | 2020 | 346 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2017 | 258 | 0.030 |
Why?
|
| Medicare | 1 | 2020 | 451 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2017 | 359 | 0.030 |
Why?
|
| Smoking | 1 | 2020 | 647 | 0.030 |
Why?
|
| Consensus | 1 | 2018 | 366 | 0.030 |
Why?
|
| Workflow | 1 | 2016 | 76 | 0.030 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2016 | 151 | 0.030 |
Why?
|
| Alemtuzumab | 1 | 2015 | 90 | 0.030 |
Why?
|
| Androgen Antagonists | 1 | 2016 | 143 | 0.030 |
Why?
|
| Esophagus | 1 | 2016 | 108 | 0.030 |
Why?
|
| Medically Uninsured | 1 | 2015 | 66 | 0.030 |
Why?
|
| Professional Practice | 1 | 2015 | 43 | 0.030 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2015 | 61 | 0.030 |
Why?
|
| Spinal Cord | 1 | 2016 | 236 | 0.030 |
Why?
|
| Actuarial Analysis | 1 | 2014 | 60 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 1909 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 916 | 0.030 |
Why?
|
| Boston | 1 | 2014 | 36 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2017 | 636 | 0.030 |
Why?
|
| Consumer Behavior | 1 | 2014 | 31 | 0.030 |
Why?
|
| Poverty | 1 | 2015 | 192 | 0.020 |
Why?
|
| Hospitals, Teaching | 1 | 2014 | 114 | 0.020 |
Why?
|
| Self Concept | 1 | 2014 | 135 | 0.020 |
Why?
|
| Program Development | 1 | 2014 | 129 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2017 | 1060 | 0.020 |
Why?
|
| Heart | 1 | 2016 | 522 | 0.020 |
Why?
|
| Marital Status | 1 | 2012 | 43 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2019 | 1269 | 0.020 |
Why?
|
| Data Collection | 1 | 2014 | 370 | 0.020 |
Why?
|
| Health Expenditures | 1 | 2013 | 98 | 0.020 |
Why?
|
| Matched-Pair Analysis | 1 | 2012 | 40 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 2012 | 195 | 0.020 |
Why?
|
| Internet | 1 | 2014 | 345 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2015 | 618 | 0.020 |
Why?
|
| Algorithms | 1 | 2019 | 1948 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2012 | 412 | 0.020 |
Why?
|
| Robotic Surgical Procedures | 1 | 2015 | 366 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2009 | 347 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 2301 | 0.020 |
Why?
|